Literature DB >> 16794255

DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses.

Liyun Shi1, Kun Luo, Dajing Xia, Taoyong Chen, Guoyou Chen, Yingming Jiang, Nan Li, Xuetao Cao.   

Abstract

Dendritic cells (DCs) are specialized antigen-presenting cells that play crucial roles in the initiation and regulation of immune responses. Maturation and activation of DCs are controlled by a balance of the inhibitory and activating signals transduced through distinct surface receptors. Many inhibitory receptors expressed by DCs have been identified, whereas the new members and their functions need further investigation. In this study, we functionally characterized DC-derived immunoglobulin receptor 2 (DIgR2) as a novel representative of a family of inhibitory receptors belonging to the immunoglobulin superfamily. We show that DIgR2 contains 2 immunoreceptor tyrosine-based inhibitory motifs (ITIMs) within its cytoplasmic region and that DIgR2 associates with Src homology-2 domain-containing protein tyrosine phosphatases-1 (SHP-1). Blockade of DIgR2 on DCs by pretreatment with DIgR2-Ig fusion protein or by silencing with specific small interfering RNA enhances DC-initiated T-cell proliferation and antigen-specific T-cell responses both in vitro and in vivo. Furthermore, immunization of mice with antigen-pulsed, DIgR2-silenced DCs elicits more potent antigen-specific CD4+ and CD8+ T-cell responses, thus protecting the vaccinated mice from tumor challenge more effectively. Our data suggest that DIgR2 is a functionally inhibitory receptor and can mediate negative signaling to regulate DC-initiated antigen-specific T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794255     DOI: 10.1182/blood-2006-04-015404

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine.

Authors:  Hongmei Xu; Xuetao Cao
Journal:  Front Med       Date:  2011-12       Impact factor: 4.592

Review 2.  Dendritic cells in human aging.

Authors:  Anshu Agrawal; Sudhanshu Agrawal; Sudhir Gupta
Journal:  Exp Gerontol       Date:  2006-12-19       Impact factor: 4.032

Review 3.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

4.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

Review 5.  The CD300 molecules: an emerging family of regulators of the immune system.

Authors:  Francisco Borrego
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

Review 6.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

7.  [Characteristics of peripheral rheograms following thermal provocation in normal and pathologic pregnancy].

Authors:  A Feiks; C Nowotny; W Gruber
Journal:  Geburtshilfe Frauenheilkd       Date:  1988-09       Impact factor: 2.915

8.  B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells.

Authors:  Yoshihisa Kobayashi; Arifumi Iwata; Kotaro Suzuki; Akira Suto; Saki Kawashima; Yukari Saito; Takayoshi Owada; Midori Kobayashi; Norihiko Watanabe; Hiroshi Nakajima
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

9.  Regulation of Immune Responses by the Activating and Inhibitory Myeloid-Associate Immunoglobuline-Like Receptors (MAIR) (CD300).

Authors:  Akira Shibuya; Chigusa Nakahashi-Oda; Satoko Tahara-Hanaoka
Journal:  Immune Netw       Date:  2009-04-30       Impact factor: 6.303

10.  Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1.

Authors:  Hongkang Xi; Kenneth J Katschke; Karim Y Helmy; Paige A Wark; Noelyn Kljavin; Hilary Clark; Jeffrey Eastham-Anderson; Theresa Shek; Merone Roose-Girma; Nico Ghilardi; Menno van Lookeren Campagne
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.